Predictors of response to terlipressin therapy in hepatorenal syndrome: Metabolomic and proteomic analysis from the CONFIRM trial
SCr, cystatin C, angiopoietin-2, and beta-2 microglobulin were associated with HRS reversal. Protein and metabolite signals centered on microbiome function and uremic toxins appeared more robust in PT patients, likely selecting a subgroup that may recover without terlipressin. Use of novel biomarkers may enrich for terlipressin response.
Authors
- Josh Levitsky (ORCID: https://orcid.org/0000-0001-7527-6093)
- Pratima Sharma (ORCID: https://orcid.org/0000-0002-1182-0579)
- Tianqi Ouyang (ORCID: https://orcid.org/0000-0001-5949-0911)
- Scott Silvey (ORCID: https://orcid.org/0000-0003-4540-4239)
- Andrew S. Allegretti (ORCID: https://orcid.org/0000-0001-9416-6623)
- Khurram Jamil (ORCID: https://orcid.org/0000-0001-9155-3513)
- Jasmohan Singh Bajaj (ORCID: https://orcid.org/0000-0003-4928-3681)
Institutions
- Northwestern University (US)
- Virginia Commonwealth University (US)
- University of Michigan (US)
- Massachusetts General Hospital (US)
- Exercise and Survivorship Education Cancer Foundation (US)
- Mallinckrodt (Ireland) (IE)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1097/hc9.0000000000000766
- Citations
- 2
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 2.64